secwatch / observer
8-K filed November 6, 2023, 6:59 PM ET ticker KRRO CIK 0001703647
M&A confidence high sentiment neutral materiality 0.95

Korro Bio, Inc. (KRRO): auditor change — Frequency closes reverse merger with Korro Bio; combined entity renamed Korro Bio, Inc.

Korro Bio, Inc.

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Nessan Bermingham

Chairperson of the Board
KRRO · Korro Bio, Inc.
Effective
2023-11-03
Filed
November 6, 2023, 6:59 PM ET
Nessan Bermingham was appointed Chairperson of the Board.
Appointed

Jean-Francois Formela

Director
KRRO · Korro Bio, Inc.
Effective
2023-11-03
Filed
November 6, 2023, 6:59 PM ET
Ram Aiyar, Ali Behbahani, Nessan Bermingham and Jean-Francois Formela (designated by Legacy Korro)
Appointed

Ram Aiyar

Director
KRRO · Korro Bio, Inc.
Effective
2023-11-03
Filed
November 6, 2023, 6:59 PM ET
Ram Aiyar, Ali Behbahani, Nessan Bermingham and Jean-Francois Formela (designated by Legacy Korro)
Departed

David Lucchino

President and Chief Executive Officer
KRRO · Korro Bio, Inc.
Effective
2023-11-03
Successor
Ram Aiyar
Filed
November 6, 2023, 6:59 PM ET
Immediately after closing of the Merger, David Lucchino, resigned as our President and Chief Executive Officer and principal executive officer.
Appointed

Ali Behbahani

Director
KRRO · Korro Bio, Inc.
Effective
2023-11-03
Filed
November 6, 2023, 6:59 PM ET
Ram Aiyar, Ali Behbahani, Nessan Bermingham and Jean-Francois Formela (designated by Legacy Korro)
Appointed

David Lucchino

Director
KRRO · Korro Bio, Inc.
Effective
2023-11-03
Filed
November 6, 2023, 6:59 PM ET
the Board was reconstituted as follows: (i) David L. Lucchino (designated by Frequency)
Departed

Cynthia L. Feldmann

Director
KRRO · Korro Bio, Inc.
Effective
2023-11-03
Filed
November 6, 2023, 6:59 PM ET
Timothy J. Barberich, Cynthia L. Feldmann, Michael Huang and Robert S. Langer resigned from the Board and committees of the Board on which they respectively served
Departed

Robert S. Langer

Director
KRRO · Korro Bio, Inc.
Effective
2023-11-03
Filed
November 6, 2023, 6:59 PM ET
Timothy J. Barberich, Cynthia L. Feldmann, Michael Huang and Robert S. Langer resigned from the Board and committees of the Board on which they respectively served
Appointed

Timothy Pearson

Director
KRRO · Korro Bio, Inc.
Effective
2023-11-03
Filed
November 6, 2023, 6:59 PM ET
Timothy Pearson (designated by mutual agreement)
Departed

Timothy J. Barberich

Director
KRRO · Korro Bio, Inc.
Effective
2023-11-03
Filed
November 6, 2023, 6:59 PM ET
Timothy J. Barberich, Cynthia L. Feldmann, Michael Huang and Robert S. Langer resigned from the Board and committees of the Board on which they respectively served
Departed

Michael Huang

Director
KRRO · Korro Bio, Inc.
Effective
2023-11-03
Filed
November 6, 2023, 6:59 PM ET
Timothy J. Barberich, Cynthia L. Feldmann, Michael Huang and Robert S. Langer resigned from the Board and committees of the Board on which they respectively served
Appointed

Ram Aiyar

Chief Executive Officer
KRRO · Korro Bio, Inc.
Effective
2023-11-03
Filed
November 6, 2023, 6:59 PM ET
Ram Aiyar, Ph.D., M.B.A. Dr. Aiyar has served as our Chief Executive Officer and a director since completion of the Merger.

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Korro Bio, Inc. engaged Ernst & Young LLP as its auditor.

Action
engagement
Auditor
Ernst & Young LLP
Exact text from the filing
Appointment of New Independent Registered Public Accounting Firm Ernst & Young LLP, or E&Y, served as the independent registered public accounting firm of Legacy Korro prior to the completion of the Merger.
View on SEC.gov
Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Korro Bio, Inc. dismissed RSM US LLP as its auditor.

Action
dismissal
Auditor
RSM US LLP
Successor
Ernst & Young LLP
Exact text from the filing
On November 3, 2023, following the completion of the Merger, RSM was dismissed as our independent registered public accounting firm.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Nessan Bermingham was appointed as Chairperson of the Board at Korro Bio, Inc..

Action
appointed
Role
Chairperson of the Board
Exact text from the filing
Nessan Bermingham was appointed Chairperson of the Board.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Jean-Francois Formela was appointed as Director at Korro Bio, Inc..

Action
appointed
Role
Director
Exact text from the filing
Ram Aiyar, Ali Behbahani, Nessan Bermingham and Jean-Francois Formela (designated by Legacy Korro)
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Ram Aiyar was appointed as Director at Korro Bio, Inc..

Action
appointed
Role
Director
Exact text from the filing
Ram Aiyar, Ali Behbahani, Nessan Bermingham and Jean-Francois Formela (designated by Legacy Korro)
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

David Lucchino resigned as President and Chief Executive Officer at Korro Bio, Inc..

Action
resigned
Role
President and Chief Executive Officer
Exact text from the filing
Immediately after closing of the Merger, David Lucchino, resigned as our President and Chief Executive Officer and principal executive officer.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Ali Behbahani was appointed as Director at Korro Bio, Inc..

Action
appointed
Role
Director
Exact text from the filing
Ram Aiyar, Ali Behbahani, Nessan Bermingham and Jean-Francois Formela (designated by Legacy Korro)
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

David Lucchino was appointed as Director at Korro Bio, Inc..

Action
appointed
Role
Director
Exact text from the filing
the Board was reconstituted as follows: (i) David L. Lucchino (designated by Frequency)
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Cynthia L. Feldmann resigned as Director at Korro Bio, Inc..

Action
resigned
Role
Director
Exact text from the filing
Timothy J. Barberich, Cynthia L. Feldmann, Michael Huang and Robert S. Langer resigned from the Board and committees of the Board on which they respectively served
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Robert S. Langer resigned as Director at Korro Bio, Inc..

Action
resigned
Role
Director
Exact text from the filing
Timothy J. Barberich, Cynthia L. Feldmann, Michael Huang and Robert S. Langer resigned from the Board and committees of the Board on which they respectively served
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Timothy Pearson was appointed as Director at Korro Bio, Inc..

Action
appointed
Role
Director
Exact text from the filing
Timothy Pearson (designated by mutual agreement)
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Timothy J. Barberich resigned as Director at Korro Bio, Inc..

Action
resigned
Role
Director
Exact text from the filing
Timothy J. Barberich, Cynthia L. Feldmann, Michael Huang and Robert S. Langer resigned from the Board and committees of the Board on which they respectively served
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Huang resigned as Director at Korro Bio, Inc..

Action
resigned
Role
Director
Exact text from the filing
Timothy J. Barberich, Cynthia L. Feldmann, Michael Huang and Robert S. Langer resigned from the Board and committees of the Board on which they respectively served
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Ram Aiyar was appointed as Chief Executive Officer at Korro Bio, Inc..

Action
appointed
Role
Chief Executive Officer
Exact text from the filing
Ram Aiyar, Ph.D., M.B.A. Dr. Aiyar has served as our Chief Executive Officer and a director since completion of the Merger.
View on SEC.gov
Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Korro Bio, Inc.: Amended and restated the Code of Conduct and Ethics in connection with the Merger.

Change
code of ethics
Exact text from the filing
the Board amended and restated our Code of Conduct and Ethics.
View on SEC.gov
Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Korro Bio, Inc.: Filed a second certificate of amendment to change the company name to 'Korro Bio, Inc.', effective upon filing on November 3, 2023 (effective 2023-11-03).

Change
charter amendment
Effective
2023-11-03
Exact text from the filing
we filed a second certificate of amendment to the Charter
View on SEC.gov
Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Korro Bio, Inc.: Approved and filed a certificate of amendment to effect a 1:50 reverse stock split, effective upon filing on November 3, 2023 (effective 2023-11-03).

Change
charter amendment
Effective
2023-11-03
Exact text from the filing
stockholders approved an amendment to our restated certificate of incorporation
View on SEC.gov
M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Korro Bio, Inc. underwent a change of control involving Korro Bio, Inc. (Legacy Korro) (closed 2023-11-03).

Action
change of control
Counterparty
Korro Bio, Inc. (Legacy Korro)
Closing
2023-11-03
Exact text from the filing
On November 3, 2023, we completed the previously announced business combination with Legacy Korro in accordance with the terms of the Merger Agreement, pursuant to which, among other matters, Merger Sub merged with and into Legacy Korro, with Legacy Korro surviving as our wholly owned subsidiary (such business combination, the Merger).
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Korro Bio, Inc. shareholders approved Approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve Proposals 1 and 2 at the 2023-11-03 meeting.

Outcome
passed
Meeting
2023-11-03
Exact text from the filing
Proposal 7 - Approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve Proposals 1 and 2. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 10,980,682 808,960 324,296 11,937,522
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Korro Bio, Inc. shareholders approved Approval of the amendment to the Charter effecting the reverse stock split at the 2023-11-03 meeting.

Proposal
reverse split
Outcome
passed
Meeting
2023-11-03
Exact text from the filing
Proposal 2 - Approval of the amendment to the Charter effecting the reverse stock split. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 22,748,459 1,021,963 281,038 0
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Korro Bio, Inc. shareholders approved Approval of the issuance of common stock in the Merger and the change in control resulting from the Merger at the 2023-11-03 meeting.

Proposal
merger approval
Outcome
passed
Meeting
2023-11-03
Exact text from the filing
Proposal 1 - Approval of the issuance of common stock in the Merger and the change in control resulting from the Merger. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 11,505,632 383,292 225,014 11,937,522
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Korro Bio, Inc. shareholders approved Approval of the Korro Bio, Inc. 2023 Stock Option and Incentive Plan at the 2023-11-03 meeting.

Proposal
equity plan
Outcome
passed
Meeting
2023-11-03
Exact text from the filing
Proposal 5 - Approval of the Korro Bio, Inc. 2023 Stock Option and Incentive Plan. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 6,321,270 5,464,618 328,050 11,937,522
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Korro Bio, Inc. shareholders approved Ratification of the appointment of RSM US LLP as our independent registered public accounting firm for the year ending December 31, 2023 at the 2023-11-03 meeting.

Proposal
auditor ratification
Outcome
passed
Meeting
2023-11-03
Exact text from the filing
Proposal 4 - Ratification of the appointment of RSM US LLP as our independent registered public accounting firm for the year ending December 31, 2023. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 23,049,119 329,237 673,104 0
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Korro Bio, Inc. shareholders approved Approval of the Korro Bio, Inc. 2023 Employee Stock Purchase Plan at the 2023-11-03 meeting.

Proposal
equity plan
Outcome
passed
Meeting
2023-11-03
Exact text from the filing
Proposal 6 - Approval of the Korro Bio, Inc. 2023 Employee Stock Purchase Plan. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 8,145,970 3,641,499 326,369 11,937,522
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Korro Bio, Inc. shareholders approved Election of one Class I director to serve until the 2026 Annual Meeting of Stockholders, and until his successor has been duly elected and qualified at the 2023-11-03 meeting.

Proposal
director election
Outcome
passed
Meeting
2023-11-03
Exact text from the filing
Proposal 3 - Election of one Class I director to serve until the 2026 Annual Meeting of Stockholders, and until his successor has been duly elected and qualified. NOMINEE Votes FOR Votes WITHHELD Broker Non-Votes David L. Lucchino 9,100,124 3,013,814 11,937,522
View on SEC.gov

8 auditor changes filed in the last 30 days. Browse all auditor changes →

Korro Bio, Inc. filing history →

Source: SEC EDGAR
accession 0001193125-23-270898
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.